Tg Therapeutics (TGTX) Research & Development (2011 - 2026)

Tg Therapeutics' Research & Development history runs 16 years deep, the most recent figure standing at $48.4 million for Q1 2026.

• In Q1 2026, Research & Development rose 4.39% year-over-year to $48.4 million; the TTM figure through Mar 2026 stood at $162.2 million (up 50.33% YoY), while the FY2025 annual figure was $160.2 million, up 69.92% from the prior year.
• Research & Development was $48.4 million for Q1 2026 at Tg Therapeutics, up from $41.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $48.4 million in Q1 2026 to a low of $14.8 million in Q3 2023.
• Historically, Research & Development has averaged $29.7 million across 5 years, with a median of $28.1 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Research & Development sank 66.97% in 2023, then soared 106.19% in 2024.
• A 5-year view of Research & Development shows it stood at $29.6 million in 2022, then sank by 41.12% to $17.4 million in 2023, then soared by 36.82% to $23.9 million in 2024, then jumped by 72.54% to $41.2 million in 2025, then rose by 17.49% to $48.4 million in 2026.
• The last three Research & Development figures came in at $48.4 million (Q1 2026), $41.2 million (Q4 2025), and $40.9 million (Q3 2025), per Business Quant data.